Stockscreener 앱 받기
71.77
4.01%
2.77
시장 영업 전:
71.74
-0.03
-0.04%
Corcept Therapeutics Inc 주식(CORT)의 최신 뉴스
Cushings Syndrome Market Exclusive Report with Detailed Study - openPR.com
How does Corcept Therapeutics Incorporated compare to its industry peersLightning-fast growth - Jammu Links News
How strong is Corcept Therapeutics Incorporated company’s balance sheetTriple-digit wealth increases - Jammu Links News
How volatile is Corcept Therapeutics Incorporated stock compared to the marketGet professional advice for market timing - Jammu Links News
Corcept Therapeutics Analyst Rating Update: Canaccord Genuity Maintains 'Buy' Rating with Lowered Price Target to 137.00 USD - AInvest
What catalysts could drive Corcept Therapeutics Incorporated stock higher in 2025Dynamic profit opportunities - Jammu Links News
Why is Corcept Therapeutics Incorporated stock attracting strong analyst attentionFastest return on investment - Jammu Links News
What are the latest earnings results for Corcept Therapeutics IncorporatedInvest smarter with daily stock recommendations - Jammu Links News
What analysts say about Corcept Therapeutics Incorporated stockRealize exceptional returns through smart trading - Jammu Links News
CORT's Q2 Earnings Beat and Pipeline Momentum: A Case for Revisiting the Downside as a Buy Opportunity - AInvest
When is Corcept Therapeutics Incorporated stock expected to show significant growthTremendous financial leverage - Jammu Links News
Corcept Therapeutics (CORT): A High-Conviction Buy Amidst Breakthroughs in Cortisol-Modulating Therapies - AInvest
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2025 Earnings Call Transcript - Insider Monkey
Corcept Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Published on: 2025-08-02 05:25:16 - metal.it
Corcept Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Corcept Therapeutics Incorporated Recovery Hinges on Volume BreakoutNews Based Entry Opportunity Alerts Detected - metal.it
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down - TradingView
A Quick Look at Today's Ratings for Corcept Therapeutics(CORT.US), With a Forecast Between $121 to $145 - 富途牛牛
Corcept Therapeutics 2025 Q2 Earnings Misses Targets as Net Income Declines 1% - AInvest
Corcept Faces Growing Pains As Earnings Miss The Mark - Finimize
Corcept Therapeutics Q2 CY2025: Revenue Misses, Earnings BeatNews and Statistics - IndexBox
Corcept: Q2 Earnings Snapshot - Connecticut Post
Earnings call transcript: Corcept Therapeutics Q2 2025 earnings beat expectations By Investing.com - Investing.com Canada
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates - Yahoo Finance
Corcept (NASDAQ:CORT) Misses Q2 Sales Targets - Yahoo Finance
Corcept Therapeutics Reports Strong Q2 Earnings, Surpassing Analyst ExpectationsNews and Statistics - IndexBox
Corcept Therapeutics falls as revenue guidance disappoints investors By Investing.com - Investing.com Canada
Corcept Therapeutics Reports Q2 2025 Financial Results - TipRanks
CORCEPT THERAPEUTICS INC SEC 10-Q Report - TradingView
Corcept Earnings: Record Patient Growth Drives 19% Revenue Jump, Pipeline Scores Multiple Wins - Stock Titan
Insiders Favor These 3 High Growth Companies - Yahoo.co
Corcept Therapeutics Announces Q2 Financial Results and Corporate Update on July 31, 2025 - AInvest
Corcept Therapeutics Advances Long-Term Safety Study of Relacorilant for Cushing Syndrome - TipRanks
Corcept Therapeutics' Q2 Earnings: A Critical Inflection Point for Growth and Innovation - AInvest
What To Expect From Corcept’s (CORT) Q2 Earnings - Yahoo.co
Technical Charts Suggest Momentum Shift in Corcept Therapeutics IncorporatedSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Published on: 2025-07-28 23:53:14 - metal.it
Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension - TipRanks
Why Corcept Therapeutics Incorporated stock attracts strong analyst attentionPortfolio Diversification Stock Ideas From Experts - beatles.ru
Why Corcept Therapeutics Incorporated stock attracts strong analyst attention Daily Equity Signal Strength Summary Report - metal.it
What are the technical indicators suggesting about Corcept Therapeutics IncorporatedInvest confidently with professional market insights - jammulinksnews.com
H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) - Yahoo Finance
Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk - Yahoo Finance
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
Corcept Therapeutics’ ALS Study: A Potential Game-Changer? - TipRanks
Should I buy Corcept Therapeutics Incorporated stock before earningsHigh-octane financial growth - jammulinksnews.com
Is Corcept Therapeutics Incorporated a good long term investmentConsistent high-performance stocks - PrintWeekIndia
What drives Corcept Therapeutics Incorporated stock priceUnbelievable profit margins - PrintWeekIndia
Is Corcept Therapeutics Incorporated stock overhyped or has real potentialFree Market Dynamics Reports - jammulinksnews.com
3.24%
자본화:
|
볼륨(24시간):